지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.1
- 수록면
- 82 - 91 (10page)
- DOI
- 10.4093/dmj.2021.0356
이용수
초록· 키워드
오류제보하기
Background: To evaluate the safety and effectiveness of empagliflozin in routine clinical settings, we collected and assessed the clinical profiles of Korean patients with type 2 diabetes mellitus.Methods: This was a post-marketing surveillance study of empagliflozin 10 and 25 mg. Information on adverse events and adverse drug reactions (ADRs) was collected as safety data sets. Available effectiveness outcomes, including glycosylated hemoglobin (HbA1c) level, fasting plasma glucose, body weight, and blood pressure, were assessed.Results: The incidence rate of ADRs was 5.14% in the safety dataset (n=3,231). Pollakiuria, pruritis genital, and weight loss were the most common ADRs. ADRs of special interest accounted for only 1.18%, and there were no serious events that led to mortality or hospitalization. In the effectiveness data set (n=2,567), empagliflozin significantly reduced the mean HbA1c level and body weight during the study period by –0.68%±1.39% and –1.91±3.37 kg (both P<0.0001), respectively. In addition, shorter disease duration, absence of dyslipidemia, and higher baseline HbA1c levels were identified as the clinical features characteristic of a “responder” to empagliflozin therapy.Conclusion: Empagliflozin is a safe and potent glucose-lowering drug in routine use among Korean patients with type 2 diabetes mellitus. It is expected to have better glycemic efficacy in Korean patients with poorly controlled type 2 diabetes mellitus.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Risk Factors Related to Serious Adverse Drug Reactions Reported through Electronic Submission during Hospitalization in Elderly Patients
Korean Journal of Family Medicine
2022 .03
-
Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
Intestinal research
2022 .07
-
Incidence and Economic Burden of Adverse Drug Reactions in Hospitalization: A Prospective Study in Korea
Journal of Korean Medical Science
2023 .02
-
단일기관에서 전산을 통해 수집된 자발적 소아 약물유해반응 보고사례의 분석
Allergy Asthma & Respiratory Diseases
2016 .01
-
단일 대학병원의 지역의약품안전센터에 보고된 소아청소년의 약물유해반응 분석
Allergy Asthma & Respiratory Diseases
2018 .01
-
L-asparaginase 약물 유해 반응 보고 분석
한국임상약학회지
2017 .01
-
중동 호흡기 증후군 치료에 사용한 항바이러스제의 약물이상반응 발현양상 분석
병원약사회지
2017 .08
-
1차 항결핵제 약물이상반응 현황: 단일기관 약물이상사례 보고사례 기반 분석
대한내과학회지
2021 .10
-
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
Diabetes and Metabolism Journal
2019 .01
-
Improvement of Glycosylated Hemoglobin in Patients with Type 2 Diabetes Mellitus under Insulin Treatment by Reimbursement for Self-Monitoring of Blood Glucose
Diabetes and Metabolism Journal
2018 .01
-
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
Diabetes and Metabolism Journal
2024 .09
-
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
Diabetes and Metabolism Journal
2024 .09
-
Long-Term Changes in HbA1c According to Blood Glucose Control Status During the First 3 Months After Visiting a Tertiary University Hospital
Journal of Korean Medical Science
2022 .10
-
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional DoseIncreasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
Endocrinology and Metabolism
2020 .01
-
Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India
셀메드
2021 .05
-
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Intestinal research
2021 .10
-
The changes of subtypes in pediatric diabetes and their clinical and laboratory characteristics over the last 20 years
Annals of Pediatirc Endocrinology & Metabolism
2016 .01
-
The Impact of IT-based Self-management Service for Type 2 Diabetes Mellitus Patients in a Community
보건의료산업학회지
2021 .09
-
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Blood Research
2022 .06
-
한방의료기관에서 자발적 보고된 한약의 약물이상사례 분석
병원약사회지
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0